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aII-Spectrin Breakdown Product Cerebrospinal Fluid
Exposure Metrics Suggest Differences in Cellular Injury
Mechanisms after Severe Traumatic Brain Injury
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Shelley C. Heaton,5 Jason A. Demery,5 Ming Cheng Liu,13 Joseph J. Tepas III,6,7 Andrea Gabrielli,6,8
Steven Robicsek,8 Kevin K.W. Wang,9,13 Claudia S. Robertson,12 and Ronald L. Hayes13

Abstract

Traumatic brain injury (TBI) produces aII-spectrin breakdown products (SBDPs) that are potential biomarkers for
TBI. To further understand these biomarkers, the present study examined (1) the exposure and kinetic characteristics of SBDPs in cerebrospinal fluid (CSF) of adults with severe TBI, and (2) the relationship between these
exposure and kinetic metrics and severity of injury. This clinical database study analyzed CSF concentrations of
150-, 145-, and 120-kDa SBDPs in 38 severe TBI patients. Area under the curve (AUC), mean residence time (MRT),
maximum concentration (Cmax), time to maximum concentration (Tmax), and half-life (t1=2) were determined for
each SBDP. Markers of calpain proteolysis (SBDP150 and SBDP145) had a greater median AUC and Cmax and a
shorter MRT than SBDP120, produced by caspase-3 proteolysis in the CSF in TBI patients ( p < 0.001). AUC and
MRT for SBDP150 and SBDP15 were significantly greater in patients with worse Glasgow Coma Scale (GCS)
scores at 24 h after injury compared to those whose GCS scores improved (AUC p ¼ 0.013, MRT p ¼ 0.001; AUC
p ¼ 0.009, MRT p ¼ 0.021, respectively). A positive correlation was found between patients with longer elevations
in intracranial pressure (ICP) measurements of 25 mm Hg or higher and those with a greater AUC and MRT for all
three biomarkers. This is the first study to show that the biomarkers of proteolysis differentially associated with
calpain and caspase-3 activity have distinct CSF exposure profiles following TBI that suggest a prominent role for
calpain activity. Further studies are being conducted to determine if exposure and kinetic metrics for biofluidbased biomarkers can predict clinical outcome.
Key words: biomarker; CSF; exposure; spectrin; traumatic brain injury

Introduction

I

n the United States, there are more than 1 million traumatic brain injury (TBI) cases annually, resulting in more
than 230,000 hospitalizations, 50,000 deaths, and 80,000 patients with disabilities (Langlois et al., 2005; Binder et al.,
2005). To date, there are no effective neuroprotective agents
for TBI patients, but biochemical markers could provide
confirmation of the injury mechanism and identify candidate

drug therapy targets (Ghanem et al., 2001; Foerch et al., 2005;
Korfias et al., 2006; Wunderlich et al., 2006; Tanaka et al.,
2007).
In a prospective case-control study, we recently determined
that aII-spectrin proteolysis, as assessed in CSF, is a potentially reliable biomarker for severe TBI in humans (Pineda
et al., 2007). This study examined changes in 150-kDa and
145-kDa aII-spectrin breakdown products (SBDPs) produced
primarily by calpain (SBDP150 and SBDP145), and 120-kDa
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SBDPs produced by caspase-3. Calpain proteolysis is primarily, but not exclusively, associated with oncotic necrosis,
while caspase-3 proteolysis is primarily associated with apoptosis (Wang, 2000). However, there is currently no literature
available on the actual cerebrospinal fluid (CSF) exposure and
kinetic characteristics of the potential brain injury biomarkers for calpain- and caspase-3–related cell death, SBDP150,
SBDP140, and SBDP120. Since these biomarkers are released
from the brain into the CSF and then potentially distributed to
other body compartments (e.g., blood), it is extremely important to define the exposure and kinetic characteristics in
the first compartment in which they are measurable in most
patients, the CSF.
This is the first study to describe the exposure and kinetic
metrics of SBDPs in the CSF of TBI patients. In addition, exposure and kinetic metric changes in relation to severity of
injury are described.
Methods
Database sample values for this study came from a prospective, case-control study that included data from two
sources: from a prospective study conducted at the University
of Florida (n ¼ 19), and from a CSF bank at Baylor College of
Medicine (n ¼ 19). The overall study was approved by the
Virginia Commonwealth University and the University of
Florida Institutional Review Board (IRB). Patients included in
the prospective, case-control study presented to the University of Florida Trauma System (Shands Hospitals in Gainesville and Jacksonville) following a severe head injury, as
defined by a GCS score of  8, and by requiring ventricular
intracranial pressure (ICP) monitoring as part of their routine
clinical care. This was a convenience sample, as not all consecutive patients were enrolled. Patients were enrolled in the
prospective study for a 16-month period, starting in April of
2003, and were followed for 6 months after study entry. The
banked samples were from patients admitted to Ben Taub
General Hospital in Houston, Texas, between August 29, 2003
and August 30, 2004 with a GCS < 8, under an IRB-approved
prospective study protocol from Baylor College of Medicine.
De-identified CSF samples and clinical information were
provided to the investigators at the University of Florida. All
patient identifiers were kept confidential by the study principal investigator (PI) at the University of Florida, and deidentified data from the study database were provided to the
PI at Virginia Commonwealth University for this analysis.
The clinical management of patients enrolled in both centers
was guided by the published ‘‘Guidelines for Management
and Prognosis of Severe Traumatic Brain Injury’’ (2000).
Patient data
Thirty-eight patients had CSF data available for exposure
and kinetic metric analysis. CSF data from samples directly
collected from the ventriculostomy catheter at 6, 12, and 24 h
post-TBI, and then every 24 h for up to 12 days were used for
the exposure and kinetic analysis of SBDP150, SBDP145, and
SBDP120. A standard protocol for CSF collection was used in
order to minimize external influences on biomarker concentration. In addition, a control group of 11 patients without TBI
who required CSF sample collection from ventriculoperitoneal shunts or intraoperatively as part of their routine care
during the study time period were also evaluated to verify
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that a change did occur in biomarker concentrations in the
TBI patients. Exposure and kinetic evaluation of the control
group CSF samples could not be done, as only one sample was
available per patient. Approximately 3–4 mL of CSF were
collected from each subject at each time point. aII-spectrin is a
non-erythrocytic protein, so it is unlikely that the presence
of blood in the CSF would confound measurements of
aII-spectrin or its degradation products. However, to limit
possible confounders, samples were immediately centrifuged
for 10 min at 48C to separate CSF from blood cells and other
debris, and immediately frozen and stored at 708 as aliquots
until the time of analysis. The time frame from sample collection to analysis varied up to 1 year, but this should not
impact concentrations, as our analysis technique has produced stable results for up to 2 years (data not shown).
An immunoblot assay was used in the prospective study to
determine the concentrations of SBDPs in the CSF samples.
The CSF samples (7 mL) were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis for 2 h. Following
electrophoresis, separated proteins were laterally transferred
to polyvinylidene fluoride for 2 h at ambient temperature in a
semi-dry transfer unit (Bio-Rad, Hercules, CA). After electrotransfer, blotting membranes were blocked for 1 h at ambient temperature, and then incubated as recommended by
the manufacturer at 48C overnight. This was followed by
three washes with tris-buffered saline tween and 2 h incubation at ambient temperature. After additional washes of the
blots, electrochemoluminescent reagents (Amersham, Pittsburgh, PA) were used to visualize the immunolabeling on
x-ray film. Molecular weights of intact aII-spectrin and SBDPs
were assessed by running alongside rainbow-colored molecular weight standards (Amersham). Quantitative evaluations
of SBDP levels were performed via computer-assisted densitometric scanning (Epson XL3500 high-resolution flatbed
scanner; Epson America, Inc., Long Beach, CA) and image
analysis with Image-J software (National Institutes of Health).
Additional details of the immunoblot assay are described
elsewhere. Arbitrary densitometric units (ADU) were used to
describe the CSF biomarker concentrations. The lower limit of
detection for this assay was 0.1 ADU.
Exposure and kinetic analysis
Exposure metrics describe the amount and duration of
biomarker exposure, and the metrics evaluated in this study
were area under the curve (AUC), mean residence time
(MRT), maximum concentration (Cmax), and time to maximum concentration (Tmax). Half-life (t1=2) was the kinetic
metric evaluated in this study and it describes the rate of
decline of the biomarker in the CSF. These exposure and
kinetic metrics were determined for each biomarker. Noncompartmental kinetic equations as described in Pharmacokinetics (Gibaldi and Peirrier, 1982) were used to determine
AUC, MRT, and t1=2. AUC and area under the first moment
curve (AUMC) were calculated by the linear trapezoidal rule
to the last observed time point and these were used to determine MRT (MRT ¼ AUMC=AUC). The rate constant for
decline (l) was estimated from log linear regression of two
points between which the greatest decrease in concentration
occurred. The rate constant for decline was used to determine
the biomarker half-life (t1=2 ¼ ln(2)=l). Biomarker Cmax and
Tmax were determined from the observed CSF concentrations.

aII-SPECTRIN EXPOSURE DIFFERENCES AFTER SEVERE TBI
Table 1. Kinetic Equations Used to Determine
Biomarker Exposure and Kinetic Metrics
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Table 2. Patient Demographics

Characteristic
AUCtrap(tn) ¼ sum i ¼ 1 to n ((ci þ ci  1) * (ti  ti  1)=2)
AUMCtrap(tn) ¼ sum i ¼ 1 to n ((ci * ti þ ci  1 * ti  1)
* (ti  ti  1)=2)
MRT ¼ AUMCtrap=AUCtrap
t1=2 ¼ ln(2)=lambda

All kinetic equations used to determine these exposure and
kinetic characteristics can be found in Table 1. Baseline levels
for the brain injury biomarkers studied were assumed to be
zero for these analyses. However, the concentration of these
biomarkers in each patient prior to their brain injury and
ventriculostomy catheter placement is unknown. In addition,
control patients from our original clinical trial showed significantly lower baseline concentrations compared to our TBI
patients (Pineda et al., 2007). Patients had a variable number
of samples available for analysis due to early discontinuation
of the ventriculostomy catheter in patients who improved,
making it medically unnecessary, or patient death. All patients with data available for a time period of more than 24 h
were included in the exposure metric analyses; however, only
patients with at least two measurable CSF biomarker levels
during the study period were included in the half-life kinetic
analysis. Thirty-two patients (84%) in this study had at least
four data points available for exposure and kinetic analyses
for the biomarkers analyzed. Seventy-eight percent of study
patients had sample data available up to 7 days post-injury
and were distributed as follows: 2 days, n ¼ 3; 3 days, n ¼ 8;
4 days, n ¼ 2; 5 days, n ¼ 4; 6 days, n ¼ 2; 7 days, n ¼ 11. The
remainder of the study patients (n ¼ 8) had samples available
up to 12 days post-injury.
Relationships between biomarker exposure
and kinetic metrics and clinical variables
The relationship between select exposure and kinetic metrics of SBDPs and clinical variables was also evaluated. These
studies focused on (1) relationships with injury magnitude,
and (2) secondary insults associated with ICP increases. Severity of injury was assessed using the post-resuscitation GCS
score. The number of hours ICP measurements were 25 mm
Hg or higher as documented hourly in the medical record up
to 7 days post-injury was used to identify patients who had
severely elevated ICP. We hypothesized that patients with
frequent severe elevations in ICP (secondary insult) would
have a greater AUC. AUC represents the concentration of
biomarker in CSF over time, and is expected to increase with
secondary insults as with increases in ICP. For the purpose of
this analysis, we used an ICP measurement breakpoint of
25 mm Hg, the recommended threshold for treatment of ICP
in severe TBI patients as set forth in the ‘‘Guidelines for
Management and Prognosis of Severe Traumatic Brain
Injury.’’
Statistical analysis
For statistical analysis, biomarker exposure and kinetic
metrics were expressed as median (range), as the data were
not normally distributed. Analysis was performed using the
Mann-Whitney U test and Kruskall-Wallis test. Correlations

Age, mean years (SD)
Gender, % male
Median scene GCS (range)
Median post-resuscitation GCS (range)
Marshall classification
Diffuse injury class I
Diffuse injury class II
Diffuse injury class III
Diffuse injury class IV
Evacuated mass lesion
Non-evacuated mass lesion
Pre-ICU hypoxia
Pre-ICU hypotension

Total (n ¼ 35)
36 (16)
77%
4 (3–8)
5 (3–8)
2
14
4
0
14
1
31%
9%

Only 35 patients had clinical data available for analysis.

were performed using the Spearman Rho. Statistical significance was set at a p < 0.05. The number of subjects at each time
point (n values) represent patients who had both clinical information and CSF samples available for analysis. All analyses were performed using the statistical software package
SPSS version 10.0.5 (SPSS, Inc., Chicago, IL).
Results
Patient demographics are shown in Table 2 and a comparison of levels of SBDPs in patients with TBI versus controls
at all time points are shown in Figure 1. Calpain-mediated
SBDP150 and SBDP145 were found to have different exposure
characteristics than the caspase-3–mediated SBDP120 marker
in the CSF of TBI patients. Table 3 shows a summary of the
median patient exposure and kinetic characteristics for the
patients included in the study. When compared to SBDP120,
the median AUC (Fig. 2) and Cmax (Fig. 3) were significantly
greater, and MRT was significantly shorter for SBDP150 and
SBDP145.
Median AUC and Cmax for SBDP150 and SBDP145 were
significantly greater in patients with no improvement or declining (worse) GCS scores at 24 h post-injury compared to
those whose GCS scores improved (AUC p ¼ 0.013, Cmax
p ¼ 0.001; AUC p ¼ 0.009, Cmax p ¼ 0.021, respectively) (Fig. 4).
MRT was shorter for SBDP120 in patients whose GCS improved versus those who did not. Evaluation of the number of
hours ICP elevations were 25 mm Hg or higher and AUC
showed that the longer the level in the ICP remained elevated,
the greater the AUC for SBDP150. As noted in Table 3, the
median Tmax and MRT were longer for SBDP120 than
SBDP145 and SBDP150, but the differences were not significant. The rates of decline (expressed as the half-life, t1=2) were
similar for all three biomarkers ( p ¼ 0.207). There was a positive correlation between the number of hours the ICP was
25 mm Hg or higher and (1) AUC (n ¼ 33) for SBDP150 [correlation coefficient 0.5; p ¼ 0.03] (Fig. 5), SBDP145 [correlation
coefficient 0.2; p ¼ 0.015], and SBDP120 [correlation coefficient
0.74; p ¼ 0.005]; (2) MRT for SBDP150 [correlation coefficient
0.41; p ¼ 0.02], SBDP145 [correlation coefficient 0.41; p ¼ 0.02],
and SBDP120 [correlation coefficient 0.48; p ¼ 0.005]; and (3)
Tmax for SBDP120 [correlation coefficient 0.48; p ¼ 0.005].
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FIG. 1. Comparison of levels of SBDPs in patients with TBI versus controls at all time points up to 5 days post-injury. Levels
of SBDP150 and SBDP145 were predominantly elevated in the first 24–72 h post-injury, while SBDP120 levels were significantly elevated at all time points except 24 h post-injury in TBI patients compared to controls (n ¼ 22–47 for each time point; *,
#, &p < 0.05 compared to controls). Values represent arbitrary densitometry units means  SEM. Reproduction of authors’
work (Pineda et al., 2007).

Discussion
aII-spectrin breakdown products are potential biomarkers
of injury severity in severe TBI patients (Pineda et al., 2007),
and the exposure and kinetic characteristics of SBDP150,
SBDP145, and SBDP120 were described for the first time in
this study. The results of this analysis show that exposure
characteristics differ for caspase-3–mediated SBDP120 and
calpain-mediated SBDP150 and SBDP145, and suggested a
potentially greater contribution of calpain activation to the
acute pathophysiology of TBI. These data support our original
study results that showed differences in the mean concentrations of these biomarkers at various time points after injury

versus control patients (Pineda et al., 2007). Associations between mean concentration of these biomarkers at selected
time points and severity of injury, such as best GCS score 1 day
post-injury, or secondary insults such as pre-ICU hypotension
were also elucidated (Pineda et al., 2007).
The amount of each biomarker present in the CSF over time
is reflected in the AUC. The AUCs for SBDP150 and SBDP145
were statistically significantly greater than the AUC for
SBDP120. We found a five and sixfold increase in the AUC of
SBDP150 and SBDP145, respectively, compared to SBDP120,
during the study period. This was possibly due to the earlier
and higher peak concentrations (Tmax and Cmax) in SBDP150
and SBDP145 that were observed compared to SBDP120. The

aII-SPECTRIN EXPOSURE DIFFERENCES AFTER SEVERE TBI
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Table 3. Summary of Median Exposure and Kinetic Characteristics for Patients with Severe TBI

Median AUC [arbitrary
densitometric units * minutes] (range)
Median MRT [hours] (range)
Mean t1=2# [hours] (range)
Median Cmax [arbitrary
densitometric units * minutes] (range)
Median Tmax [hours] (range)

SBDP150
(n ¼ 38)

SBDP145
(n ¼ 38)

SBDP120
(n ¼ 38)

317384
(16766–1313176)
52
(16–160)
24
(5–108)
132
(3–190)
34
(3–240)

389759
(24275–1396481)
55
(17–191)
23
(4–217)
137
(10–208)
34
(3–240)

61530
(0–635663)
65
(0–179)
40
(4–347)
20
(0–146)
56
(3–240)

p Value
< 0.001
< 0.001
< 0.176
< 0.001
< 0.086

#

SBDP150 (n ¼ 34); SBDP145 (n ¼ 35); SBDP120 (n ¼ 25).

median Cmax for SBDP150 and SBDP145 was approximately 6.5-fold higher than the Cmax observed for SBDP120
( p < 0.001), with the highest Cmax observed for SBDP120 being similar to the median Cmax for SBDP150 and SBDP145,
and occurring 10 days post-injury. The median Tmax (time to
Cmax) was 1.5-fold longer for SBDP120 compared to the other
two biomarkers; however, statistically significant differences
were not found during the short time period of this study
( p ¼ 0.086). The increased amount of exposure indicated by
calpain- versus caspase-3–biomarker AUC and Cmax suggest
more calpain than caspase-3 activity acutely after TBI. This
suggests a predominance of necrosis versus apoptotic cell
death acutely following TBI. However, it is possible that ac-

tivation of these proteases may be related to other functions of
activation of these proteases, including synaptic remodeling
(Wu and Lynch, 2006; Louneva et al., 2008; Liu et al., 2006). To
fully understand caspase-3 activity and changes in SBDP120,
studies with a longer duration of evaluation need to be conducted.
The median half-life was approximately 1 day for SBDP150
(n ¼ 34) and SBDP145 (n ¼ 35), and was 1.5 days for SBDP120
(n ¼ 25). The half-life was determined from the rate of decline
between only two time points in most patients, which warrants cautious interpretation. The average amount of time it
takes a majority (approximately two-thirds) of the biomarkers
to be eliminated from the CSF (duration of exposure) is
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FIG. 2. Comparison of median area under the curve (AUC)
for SBDP150, SBDP145, and SBDP120. The differences in
AUC were statistically significant between SBDP150 and
SBDP120 ( p < 0.001), and also between SBDP145 and
SBDP120 ( p < 0.001). There was no significant difference between SBDP150 and SBDP145. AUC is expressed in arbitrary
densitometric units (adu)*min. The line in the box indicates
the median value of the data, the upper edge of the box indicates the 75th percentile of the data set, and the lower edge
indicates the 25th percentile. The ends of the vertical lines
indicate the minimum and maximum data values (#p < 0.05
compared to SBDP120).

SBDP145

SBDP120

FIG. 3. Comparison of maximum concentrations (Cmax) for
SBDP150, SBDP145, and SBDP120. The differences in median Cmax were significant between SBDP150 and SBDP120
( p < 0.001), and also between SBDP145 and SBDP120 ( p <
0.001). There was no significant difference between SBDP150
and SBDP145. Cmax is expressed in arbitrary densitometric
units (adu). The line in the box indicates the median value of
the data, the upper edge of the box indicates the 75th percentile of the data set, and the lower edge indicates the 25th
percentile. The ends of the vertical lines indicate the minimum
and maximum data values (#p < 0.05 compared to SBDP120).
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FIG. 4. Comparison of area under the curve (AUC) and changes in GCS scores from post-resuscitation to day 1. There was a
statistically significant difference in median AUC for SBDP150 ( p ¼ 0.013) and SBDP145 ( p ¼ 0.009), but not SBDP120
( p ¼ 0.322), between patients who had no improvement or worsening GCS (n ¼ 22), compared to those who improved
(n ¼ 13) during this time period. AUC is expressed in arbitrary densitometric units (adu)*min. The line in the box indicates the
median value of the data, the upper edge of the box indicates the 75th percentile of the data set, and the lower edge indicates
the 25th percentile. The ends of the vertical lines indicate the minimum and maximum data values (&p < 0.05 compared to
SBDP150 in the improved group; #p < 0.05 compared to SBDP145 in the improved group).

expressed by the MRT. MRT is calculated by dividing the
AUC by the AUMC (Table 1), which takes into account how
fast the biomarkers are produced and how fast they decline.
This delay in the Cmax suggests that caspase-3–mediated apoptotic injury and cell death continues beyond the time period
of our study, and SBDP120 may not even reach its maximum
concentration until much later in the course of injury. The
MRT ranged from approximately 2 (SBDP150 and SBDP145)
to 3 (SBDP120) days, and the differences were statistically

significant ( p < 0.001). The shorter MRT for calpain-associated SBDPs, in addition to the AUC and Cmax findings, support the suggestion of acute ‘‘over-activation’’ of calpain
versus caspase-3 proteolysis after TBI. Ongoing SBDP biomarker studies evaluating these kinetic and exposure characteristics over a longer period of time will provide additional
insight into the duration of CSF calpain and caspase-3 activity.
Overall, direct comparisons of the exposure and kinetic
characteristics for SBDP150, SBDP145, and SBDP120, show

aII-SPECTRIN EXPOSURE DIFFERENCES AFTER SEVERE TBI

AUC (adu*min) SBDP150

1,400,000
1,200,000
1,000,000
800,000
600,000
400,000
200,000
0
0

20

40

60

80

100

Total hours of intracranial hypertension
(ICP 25 mm Hg)

FIG. 5. Correlation between the number of hours ICP elevations were 25 mm Hg or higher and area under the curve
(AUC) for SBDP150. This figure shows the positive correlation between the number of hours ICP was 25 mm Hg or
higher and AUC (n ¼ 33) for SBDP150 [correlation coefficient
0.5; p ¼ 0.003]. AUC is expressed in arbitrary densitometric
units (adu)*min.

that there is a statistically significant difference in the amount
of biomarker produced over a period of time (AUC), the duration of exposure of the biomarkers (MRT), and the peak
concentration (Cmax) of biomarkers observed. These exposure-characteristic differences suggest that calpain may play a
relatively greater role in acute pathological responses to TBI
than caspase-3, which may indicate a predominance of necrotic versus apoptotic cell death.
Exposure and kinetic characteristics of these biomarkers
were also compared to initial severity of injury as assessed by
GCS. There were no statistically significant differences in the
biomarker exposure or kinetic characteristics for patients with
a post-resuscitation GCS of 3–5 versus a GCS of 6–8. The
median AUC, MRT, Cmax, and Tmax were also compared to the
change in GCS from post-resuscitation until day 1 (best day
1 GCS score). Using the 24-h trend in GCS score reduces the
influence of factors other than severity of injury, but inherent
limitations of the GCS cannot be completely avoided. The
AUC and Cmax for SBDP150 and SBDP145 were less than
those for patients who improved over this short period of
time, with the AUC decreasing by approximately half. There
was no change in AUC or Cmax for SBDP120; however, the
MRT was significantly shorter for SBDP120 in patients that
improved compared to those who had no improvement or
worsening GCS. As expected, patients in whom GCS improved in the first 24 h have less biochemical evidence of brain
injury or SBDP150 and SBDP145. The MRT is probably the
best kinetic estimate of the clinical duration of biomarker
production after injury. These differences in GCS and biomarker exposure metrics could be influenced by differences in
management between the two groups of patients and reflect
response to management more than severity of injury.
We also compared AUC, MRT, Cmax, and Tmax to the
number of hours documenting ICP of 25 mm Hg or higher to
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try to evaluate if those with more hours of ICP elevations had
greater biomarker production than those with fewer documented hours of elevations in ICP. Patients who had more
hours of elevations in ICP had statistically significant increases in AUC and MRT for all three biomarkers, indicating
that patients who have longer elevations in ICP also have
increases in the amount and duration of SBDP production.
Tmax for SBDP120 also increased with longer durations of elevated ICP. These comparisons of severity of injury and exposure metrics suggest that production of SBDP150, SBDP145,
and SBDP120 increase when the severity of injury increases, or
when severe TBI is associated with repeated secondary increases in ICP, a potential additional injury adversely affecting outcome.
Overall, studies analyzing exposure and kinetic characteristics of CSF brain injury biomarkers are scarce. This pilot
study provides the first rigorous assessment of SBDP exposure and kinetic metrics and lays the necessary foundation for
future research. However, there are some limitations to an
exposure and kinetic study of CSF biomarkers. This is an exposure and kinetic analysis of a prospective, case-control
clinical study database; therefore, it is limited to the patient
data that were documented for the original study and the
biomarker concentrations time points available. Since there
are no previous studies modeling the compartmental distribution of the biomarkers in the CSF, non-compartmental
pharmacokinetic metrics were used. Baseline concentrations
of these biomarkers are unknown; therefore, an assumption
was made for the concentration at time zero. CSF samples
were not available for all time points, as the rapidly changing
clinical condition of these critically ill patients made sample collection very difficult. Therefore, all available samples
were included in the exposure and kinetic analyses to maximize the sample size for this analysis. Additionally, a majority
of the data available for analysis in this pilot study were from
admission up to 7 days post-injury, so the full kinetic profile of
SBDP120, whose peak concentration appears to be prolonged
compared to SBDP150 and SBDP145, could not be fully elucidated. The AUC and MRT calculations were calculated only
from the time the ventricular catheter was inserted until the
time it was discontinued or the death of the patient; therefore,
the time period for sample collection was not consistent between patients and the results may not be completely comparable. However, these data provide an initial assessment of
relationships between exposure metrics and TBI injury processes.
It is not known how ventriculostomy drainage affects the
concentration of these biomarkers in the CSF, and both intermittent and continuous drainage methods were used in
the patients included in our study. Multiple confounders,
such as duration of biomarker production, continuous CSF
production, and the fact that TBI patients require CSF
drainage during periods of elevated ICP, make it extremely
difficult to determine if and=or how CSF ventriculostomy
drainage impacts the exposure and kinetic characteristics of
these biomarkers. Shore and colleagues suggest that continuous versus intermittent ventricular catheter drainage
affects biomarker concentrations, with higher CSF biomarker
concentrations occurring in patients with intermittent
drainage (Shore et al., 2004). The authors of this small study
point out multiple confounders that make it difficult to
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determine a cause-and-effect relationship between these
methods of drainage. Without a consistent rate of CSF
drainage from the ventriculostomy catheter, and without
knowing how the biomarkers distribute into other compartments, it is difficult to determine how the biomarker concentrations are affected by CSF drainage. Ongoing studies by
our group are currently addressing this question. Finally, our
analysis of relationships between exposure and kinetic metrics and ICP is limited by the fact that ICP information
was obtained from the medical record. Future studies using
high-resolution ICP data collection may further refine this
analysis.
In summary, the data presented here are the first attempt
to describe CSF exposure and kinetic characteristics of biomarkers after severe TBI. These initial assessments have
provided potentially important insights into differences between the accumulation of biomarkers possibly reflecting
calpain activity (SBDP150 and SBDP145) versus a biomarker
of caspase-3 activity (SBDP120). We consistently observed
evidence of a greater production of calpain-mediated biomarkers than caspase-3–mediated biomarkers in the acute
phase following severe TBI. In addition, calpain markers, but
not the caspase-3 marker, were reliably associated with acute
injury magnitude. Increases in both calpain and caspase-3
markers were correlated with secondary increases in ICP.
Thus, calpain-mediated necrotic mechanisms may be a major
contributor to acute pathophysiological responses to TBI, as
well as secondary insults produced by increased ICP.
However, the limited time frame of this study did not allow
more definitive characterization of potentially delayed and
prolonged changes in the exposure and kinetic metrics of
SBDP120, a possible biomarker of apoptotic mechanisms.
This delayed profile for manifestation of apoptotic processes
is consistent with a number of laboratory observations
suggesting a sustained and delayed profile for apoptotic cell
death (Wang, 2000; Nath et al., 1999). More detailed studies
will provide critical information on the temporal characteristics of these two important cell death mechanisms.
Calpain activity markers (SBDP145 and SBDP150) were
found to have different exposure characteristics than the
caspase-3–mediated SBDP120, in the CSF of TBI patients.
These exposure differences suggest that different proteolytic
mechanisms occur after severe TBI over time, with calpain
‘‘over-activation’’ occurring sooner than caspase-3 ‘‘overactivation.’’ Ongoing studies by our group are currently being
conducted to more fully elucidate calpain- and caspase-3–
mediated SBDP biomarker exposure and kinetic metrics in
CSF and blood, and their relationships to severity of injury
and clinical outcomes in severe TBI patients, as well as the
contribution of CSF drainage techniques to exposure and
kinetic metrics.
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